Minot DeBlois Advisors’s Biogen BIIB Stock Holding History

Minot DeBlois Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20	Closed	-$2.74K	–	253
2025 Q1	$2.74K	Sell	20 -12	-38%	-$1.72K	﹤0.01%	225
2024 Q4	$4.89K	Buy	+32	New	+$5.4K	﹤0.01%	248

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Minot DeBlois Advisors's BIIB Position: Q2 2025 in Review

Minot DeBlois Advisors sold out of Biogen (BIIB) in Q2 2025, closing a stake of 20 shares — an estimated $2.74K sold.

Minot DeBlois Advisors first reported a position in BIIB in Q4 2024 and held it in 2 quarters. The position peaked at $4.89K in Q4 2024. 866 funds tracked by Wall St. Rank hold BIIB as of Q2 2025.

Minot DeBlois Advisors reported no remaining Biogen position as of Q2 2025 after selling out during the quarter.
Minot DeBlois Advisors sold 20 Biogen shares in Q2 2025, an estimated $2.74K.
Minot DeBlois Advisors first reported a position in Biogen in Q4 2024 and held it in 2 quarters.
Minot DeBlois Advisors's Biogen position peaked at $4.89K in Q4 2024.
866 funds tracked by Wall St. Rank held Biogen as of Q2 2025.

Based on Minot DeBlois Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.